Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glia maturation factor beta pseudogene 1 (GMFBP1) is classified as a pseudogene corresponding to the protein-coding gene glia maturation factor beta (GMFB). Pseudogenes are non-functional sequences in the genome that resemble protein-coding genes but generally lack the ability to produce functional proteins. As such, GMFBP1 has no known biological function, disease association, or role as a therapeutic target. It does not serve as a biomarker, is not known to interact with drugs, and does not participate in molecular pathways relevant to therapeutic intervention. If you were seeking information on the functional gene (GMFB, glia maturation factor beta), please clarify, as GMFB is a protein with known biological function in glial cell differentiation and neurodevelopment. The current query, as written, covers a pseudogene, which is not a drug target and lacks clinical relevance. No information specific to GMFBP1 is present in common scientific databases, and its status as a pseudogene precludes it from classification as a therapeutic or diagnostic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glia maturation factor beta pseudogene 1 (GMFBP1).